Journal
JOURNAL OF LEUKOCYTE BIOLOGY
Volume 98, Issue 2, Pages 143-152Publisher
WILEY
DOI: 10.1189/jlb.3HI1014-493R
Keywords
fibroblasts; asbestos; IRS-1
Categories
Funding
- American Lung Association Senior Fellowship Research Award
- U.S. National Institutes of Health/National Heart, Lung, and Blood Institute [R01HL108979]
- Sidney Kimmel Foundation
Ask authors/readers for more resources
IPF is a progressive lung disorder characterized by fibroblast proliferation and myofibroblast differentiation. Although neutrophil accumulation within IPF lungs has been negatively correlated with outcomes, the role played by neutrophils in lung fibrosis remains poorly understood. We have demonstrated previously that NE promotes lung cancer cell proliferation and hypothesized that it may have a similar effect on fibroblasts. In the current study, we show that NE-/- mice are protected from asbestos-induced lung fibrosis. NE-/- mice displayed reduced fibroblast and myofibroblast content when compared with controls. NE directly both lung fibroblast proliferation and myofibroblast differentiation in vitro, as evidenced by proliferation assays, collagen gel contractility assays, and alpha SMA induction. Furthermore, aSMA induction occurs in a TGF-beta-independent fashion. Treatment of asbestos-recipient mice with ONO-5046, a synthetic NE antagonist, reduced hydroxyproline content. Thus, the current study points to a key role for neutrophils and NE in the progression of lung fibrosis. Lastly, the study lends rationale to use of NE-inhibitory approaches as a novel therapeutic strategy for patients with lung fibrosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available